Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
The new data now underscores LODERs additional potential to increase the resectability of tumors, opening up more surgical options for patients with otherwise inoperable pancreatic cancer.Silexion Therapeutics Corp. (NASDAQ:SLXN) stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.
Silexion Therapeutics公司（納斯達克：SLXN）股價在週二的美股盤前交易中上漲了21.72%以上，原因是該公司公佈了首代產品LODER的2期試驗新發現。
Overall, the updated analysis reveals a 56% objective response rate (ORR) in patients treated with LODER, with the ORR increasing to 67% in patients whose previously non-resectable tumors became resectable.
總體而言，更新的分析顯示在接受LODER治療的患者中達到了56%的客觀反應率（ORR），在以往無法手術的腫瘤變得可手術的患者中，ORR增至67%。
Silexion had previously reported that patients treated with LODER combined with standard-of-care (SoC) chemotherapy experienced a 9.3-month improvement in overall survival (OS) compared to chemotherapy alone.
Silexion此前報告稱，接受LODER與標準治療（SoC）化療聯合治療的患者的總生存（OS）較僅接受化療的患者提高了9.3個月。
The new data now underscores LODERs additional potential to increase the resectability of tumors, opening up more surgical options for patients with otherwise inoperable pancreatic cancer.
新數據現在強調了LODER進一步增加腫瘤可手術性的潛力，爲否則無法手術的胰腺癌患者提供更多外科手術選擇。
Silexion is also progressing with the development of its next-generation product, SIL-204, which builds upon the efficacy of the LODER.
Silexion也在推進其下一代產品SIL-204的開發，該產品基於LODER的療效進一步發展。
SIL-204 is designed to target a broader range of KRAS mutations.
SIL-204旨在針對更廣泛範圍的KRAS突變。
In August, Silexion Therapeutics and Moringa Acquisition Corp, a publicly-traded special purpose acquisition company, combined with Biomotion Sciences.
今年8月，Silexion Therapeutics與一家公開交易的特殊目的收購公司Moringa Acquisition Corp合併，並與Biomotion Sciences合併。
The combined company's name changed from Biomotion Sciences to Silexion Therapeutics.
合併後的公司更名爲Silexion Therapeutics，前身爲Biomotion Sciences。
Price Action: SLXN stock is up 18.3% at $0.91 during the premarket session at last check Tuesday, according to Benzinga Pro.
價格走勢：SLXN股票在納斯達克盤前交易中上漲了18.3%，報0.91美元，根據彭博專業版最新數據顯示週二。
- T-Mobile To Raise $2.5B Via Debt For Buybacks and Growth.
- T-Mobile將通過債務籌集250億美元用於股票回購和增長。
譯文內容由第三人軟體翻譯。